Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
March 3, 2022
RegMed Investors’ (RMi) closing bell: a worried sector, downtrodden by war anxieties
March 2, 2022
RegMed Investors’ (RMi) closing bell: a wild up and down open as cell and gene therapy sector closes positive
March 2, 2022
RegMed Investors’ (RMi) pre-open: after a sell-off, a pop and a profit mode?
March 1, 2022
RegMed Investors’ (RMi) closing bell: the wall-of-worry wavers from sector’s risk-off to risk-on
March 1, 2022
RegMed Investors’ (RMi) pre-open: a volatile, earnings and headline driven sector and market
February 28, 2022
RegMed Investors’ (RMi) closing bell: despite starting with a sell-off, the cell and gene therapy reaped a bare upside as the oversold lost and gained momentum
February 28, 2022
RegMed Investors’ (RMi) pre-open: Again, I ask what’s sustainable in this warring geo-political turmoil?
February 25, 2022
RegMed Investors’ (RMi) closing bell: share pricing risk decline from a headline drive market to close sector positive
February 25, 2022
RegMed Investors’ (RMi) pre-open: turning or burning - the sector correction beyond the invasion of Ukraine
February 24, 2022
RegMed Investors’ (RMi) closing bell: a lot of buys on first day of a disclosed Ukraine attack
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors